Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Inclusion criteria

• Men and women aged >18 years
• Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
• Able to provide informed consent

Exclusion criteria

• Pathologic evidence of pancreatic cancer
• Pregnant or breast-feeding patients
• Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
• Inability to lay flat or meet the standard requirements of traditional MRI
• Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay

• Bilirubin > 1.5 x ULN
• AST/ALT > 2.5 x ULN
• Albumin < 3 g/dL
• GGT > 2.5 x ULN if Alkaline Phosphatase > 2.5 x ULN
• Renal function with Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min, from assays obtained within 6 weeks prior to study enrollment
• Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment.